This last decade, AMPK has often been presented as a potential therapeutic target in many cardiovascular diseases since its pharmacological stimulation has been shown to be beneficial for the pathological heart under many circumstances such as ischemia/reperfusion, diabetic cardiomyopathy, pathological hypertrophy or heart failure (HF) [23–26]. Here, PRKAA2 is linked to cardiovascular disorder.